Back to results
US 2017/0319870 A1Published application
Prevention and screening method
OwnerAnn LIEBERT, Roberta CHOW +1inventors
InventorsAnn LIEBERT, Roberta CHOW, Euahna VARIGOS
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerAnn LIEBERT, Roberta CHOW +1inventors
InventorsAnn LIEBERT, Roberta CHOW, Euahna VARIGOS
Estimating the term…
The present invention relates to a method of preventing or reducing one or more adverse post-anaesthetic effects in a patient, comprising treating the patient with low level laser therapy (LLLT) prior to anaesthesia and/or during anaesthesia and/or following anaesthesia, and to a method for assessing whether a patient is at risk of suffering from adverse post-anaesthetic effects, comprising determining whether the patient contains a polymorphism in a gene encoding one of the following proteins: (a) protein associated with assembly and disassembly of microtubules; (b)ion channel protein; (c) membrane stability protein; (d) Melanocortin systems proteins; (e) proteins associated with Alzheimer's and/or Parkinson's vulnerability; or (f) proteins associated with migraine.
A method of preventing or reducing one or more adverse post-anaesthetic effects in a patient, comprising treating the patient with low level laser therapy (LLLT) prior to anaesthesia and/or during anaesthesia and/or following anaesthesia.
A method of reducing or preventing adverse post-anaesthetic effects in a patient, comprising treating the patient with low level laser therapy (LLLT) prior to anaesthesia, wherein the LLLT is administered at a wavelength in the range of from 600 nm to 950 nm, and an energy density per dose in the range of from 0.5 to 5 Joules/cm2.
A method of reducing or preventing one or more adverse post-anaesthetic effects selected from the group consisting of pain, nausea and vomiting, dizziness, blurred vision, dementia, the method comprising treating the patient with low level laser therapy (LLLT) prior to anaesthesia, wherein the LLLT is administered at a wavelength in the range of from 600 nm to 950 nm and an energy density per dose in the range of from 0.5 to 5 Joules/cm2.
A method of reducing or preventing post-anaesthetic dementia in a patient, comprising treating the patient with low level laser therapy (LLLT) prior to anaesthesia, wherein the LLLT is administered at a wavelength in the range of from 600 nm to 950 nm and an energy density per dose in the range of from 0.5 to 5 Joules/cm2.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A low level laser device or LED device when used for preventing or reducing post-anaesthetic dementia in a patient undergoing anaesthesia, wherein the device is arranged to administer LLLT to the patient prior to anaesthesia, and/or during anaesthesia and/or following anaesthesia.
Dependencies are inferred from the claim text.